? CORE A The Administrative and Biostatistics Core (referred to as Core A). Core A has two interrelated components: Administrative and Biostatistics, which serve to advance the missions of the P01 that are not able to be served by other entities. The overriding objectives or Specific Aims of the Administrative component, under the direction of Dr. Anil Rustgi (also overall Director of Core A), is to coordinate an integrated research program between the Projects and with strong support from the scientific Cores. This Administrative component also facilitates interactions with Penn's Perelman's School of Medicine, its NCI designated Abramson Cancer Center, external institutions, enrichment programs, career development pathways, catalyzes new directions for our P01, and ensures that the P01 has the unequivocal and wholehearted institutional support. The Biostatistics component, under the direction of Dr. Qi Long, Professor of Biostatistics, is located in the Penn Center for Clinical Epidemiology and Biostatistics (CCEB). Its objectives or Specific Aims are to provide comprehensive support for the Projects in experimental design, statistical modeling/analysis, data interpretation and methodological investigations. In aggregate, this Core enables innovative basic science research with translation of robust preclinical models into new perspectives in therapeutics of esophageal cancer, which is a major gap in the field.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA098101-18
Application #
9912112
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Karakasheva, Tatiana A; Dominguez, George A; Hashimoto, Ayumi et al. (2018) CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight 3:
Liu, Yang; Sethi, Nilay S; Hinoue, Toshinori et al. (2018) Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33:721-735.e8
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Deng, Jiehui; Wang, Eric S; Jenkins, Russell W et al. (2018) CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8:216-233
Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970
Kasagi, Yuta; Chandramouleeswaran, Prasanna M; Whelan, Kelly A et al. (2018) The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes. Cell Mol Gastroenterol Hepatol 5:333-352
Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48
Campbell, Joshua D; Yau, Christina; Bowlby, Reanne et al. (2018) Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23:194-212.e6
Whelan, Kelly A; Muir, Amanda B; Nakagawa, Hiroshi (2018) Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. Cell Mol Gastroenterol Hepatol 5:461-478

Showing the most recent 10 out of 173 publications